- Public Comps
- Bruker
Bruker Valuation Multiples
Discover Bruker's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Masimo, Demant, Sysmex, Shimadzu and more.
Bruker Overview
About Bruker
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Founded
1991
HQ

Employees
11.1K
Website
Financials (LTM)
EV
$10B
Valuation Multiples
Start free trialBruker Financials
Bruker reported last 12-month revenue of $3.5B and EBITDA of $610M.
In the same LTM period, Bruker generated $1.8B in gross profit, $610M in EBITDA, and $310M in net income.
Revenue (LTM)
Bruker P&L
In the most recent fiscal year, Bruker reported revenue of $3.4B and EBITDA of $288M.
Bruker is unprofitable as of last fiscal year, with gross margin of 46%, EBITDA margin of 8%, and net margin of (0%).
Financial data powered by Morningstar, Inc.
Bruker Stock Performance
Bruker has current market cap of $8.5B, and enterprise value of $10B.
Market Cap Evolution
Bruker's stock price is $56.03.
Bruker share price decreased by 3.4% in the last 30 days, and increased by 72.7% in the last year.
Bruker has an EPS (earnings per share) of $-0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $8.5B | -3.4% | -3.4% | -6.8% | 72.7% | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBruker Valuation Multiples
Bruker trades at 2.9x EV/Revenue multiple, and 16.7x EV/EBITDA.
EV / Revenue (LTM)
Bruker Financial Valuation Multiples
As of September 2, 2026, Bruker has market cap of $8.5B and EV of $10B.
Bruker has a P/E ratio of 27.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bruker Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Bruker Margins & Growth Rates
Bruker grew revenue by 4% and EBITDA by 124% in the last fiscal year.
In the most recent fiscal year, Bruker reported gross margin of 46%, EBITDA margin of 8%, and net margin of (0%).
Bruker Margins
Bruker Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bruker Operational KPIs
Bruker's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Bruker's Rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bruker's Rule of X is 27% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Bruker Competitors
Bruker competitors include Masimo, Demant, Sysmex, Shimadzu, Caris Life Sciences, Bio-Rad Laboratories, Getinge, Insulet, Glaukos and Ypsomed.
Most Bruker public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.4x | 6.4x | 21.2x | 21.2x | |||
| 3.5x | 3.1x | 15.7x | 13.3x | |||
| 2.4x | 2.3x | 12.1x | 11.5x | |||
| 1.8x | 1.8x | 10.2x | 10.4x | |||
| 8.2x | 7.0x | (1301.5x) | 39.6x | |||
| 3.8x | 3.8x | 8.8x | 22.6x | |||
| 2.2x | 2.1x | 13.0x | 10.8x | |||
| 4.0x | 3.5x | 23.5x | 14.3x | |||
This data is available for Pro users. Sign up to see all Bruker competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Bruker
Bruker has acquired 33 companies to date.
Last acquisition by Bruker was on August 10th 2026. Bruker acquired Mimetas for undisclosed valuation.
Latest Acquisitions by Bruker
| Description | Mimetas is a Netherlands-headquartered biotechnology firm specializing in organ-on-a-chip models. Its OrganoPlates support high-throughput screening of organotypic cell cultures, bridging the gap between traditional in vitro, animal models, and human patient outcomes to improve drug predictability and development. | - | Biocrates Life Sciences is an Austrian company specializing in targeted metabolomics kits for biomarker discovery and validation in precision medicine. Its MxP Quant 500 kit enables absolute quantification of over 630 metabolites across 61 pathways using LC-MS technology, supporting research in oncology, neurology, and cardiology. The platform includes automated sample preparation with the EVO kit and cloud-based MetaboAnalyst software for data processing. Innsbruck-headquartered since 1998, Biocrates serves academic labs and pharma companies worldwide, including collaborations with Roche and AstraZeneca. | RECIPE is a Munich-based manufacturer of CE-IVD certified clinical diagnostic kits for HPLC, LC-MS/MS, and photometry. The company supplies full kits, calibrators, controls, internal standards, and optimization mixes for therapeutic drug monitoring and toxicology. Established in 2005, RECIPE supports labs in over 50 countries with validated methods for immunosuppressants and vitamin D analysis. | |
| HQ Country | |||||
| HQ City | Leiden | - | Innsbruck | Munich | |
| Deal Date | 10 Aug 2026 | 8 Jan 2026 | 3 Jun 2025 | 16 Apr 2025 | |
| Valuation | undisclosed | undisclosed | $108M | $89M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Bruker acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Bruker
Bruker has invested in 10 companies to date.
Latest investment by Bruker was on August 11th 2026. Bruker invested in Atinary in their Strategic investment round.
Latest Investments by Bruker
| Description | Atinary is a Paris-headquartered AI platform for R&D digitization in life sciences. It provides machine learning tools, robotics automation, and cloud workflows for drug discovery, materials science, and biotech experiments. The end-to-end system accelerates lab processes for pharmaceutical companies and research institutes across Europe and the United States. | Mercy BioAnalytics is a diagnostics company developing blood tests for early-stage cancer detection using extracellular vesicles. Its platform analyzes EV biomarkers from liquid biopsies to identify stage I tumors in lung and breast cancers. Natick-headquartered since 2018, Mercy BioAnalytics collaborates with Mayo Clinic for clinical validation and plans FDA submissions in 2024. | Terrain BioSciences is a Boston-based biotechnology firm specializing in RNA therapeutics and vaccine platforms. It employs artificial intelligence alongside proprietary lipid nanoparticle manufacturing to optimize RNA sequence design, stability, and delivery. The company collaborates with more than twelve biotech partners to improve expression levels and accelerate clinical timelines for personalized cancer vaccines and infectious disease treatments. Terrain BioSciences focuses on mRNA modalities for oncology and immunology applications. | PrognomiQ is a proteomics company generating multi-omics datasets for early disease detection. Headquartered in San Francisco, it maps proteomes alongside genomics and metabolomics to uncover biomarkers for cancer and neurodegenerative disorders. PrognomiQ's platform powered the largest human plasma proteome map published in 2023. | |
| HQ Country | |||||
| HQ City | Lausanne | Boston, MA | - | San Francisco, CA | |
| Deal Date | 11 Aug 2026 | 3 Sep 2025 | 12 Feb 2025 | 5 Nov 2024 | |
| Round | Strategic investment | Series B | Seed | Series D | |
| Raised | undisclosed | $59M | $9M | $34M | |
| Investors | Bruker | Sozo Ventures; iSelect Fund; Portfolia; Novalis LifeSciences; BrightEdge (American Cancer Society VC unit); Labcorp; Mindshift Capital; Perceptive Xontogeny Venture Fund; Hologic; Avestria Ventures; Bruker | Uncommon Denominator; John Evans; John Maraganore; Hawktail Management; Olive Capital; Magnetic Ventures; Rogue Capital Partners; Brainstorm Ventures; Hans Bishop; Josef Feldman; Bruker | Seer; aMoon Fund; Invus; Catalio Capital Management; Bruker | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Bruker investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bruker
| When was Bruker founded? | Bruker was founded in 1991. |
| Where is Bruker headquartered? | Bruker is headquartered in United States. |
| How many employees does Bruker have? | As of today, Bruker has over 11K employees. |
| Is Bruker publicly listed? | Yes, Bruker is a public company listed on Nasdaq. |
| What is the stock symbol of Bruker? | Bruker trades under BRKR ticker. |
| When did Bruker go public? | Bruker went public in 2000. |
| Who are competitors of Bruker? | Bruker main competitors include Masimo, Demant, Sysmex, Shimadzu, Caris Life Sciences, Bio-Rad Laboratories, Getinge, Insulet, Glaukos, Ypsomed. |
| What is the current market cap of Bruker? | Bruker's current market cap is $8.5B. |
| What is the current revenue of Bruker? | Bruker's last 12 months revenue is $3.5B. |
| What is the current revenue growth of Bruker? | Bruker revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Bruker? | Current revenue multiple of Bruker is 2.9x. |
| What is the current EBITDA of Bruker? | Bruker's last 12 months EBITDA is $610M. |
| What is Bruker's EBITDA margin? | Bruker's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Bruker? | Current EBITDA multiple of Bruker is 16.7x. |
| What is the current FCF of Bruker? | Bruker's last 12 months FCF is $125M. |
| What is Bruker's FCF margin? | Bruker's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Bruker? | Current FCF multiple of Bruker is 81.7x. |
| How many companies Bruker has acquired to date? | As of September 2026, Bruker has acquired 33 companies. |
| What was the largest acquisition by Bruker? | $940M acquisition of Elitech Group on 27th December 2023 was the largest M&A Bruker has done to date. |
| What companies Bruker acquired? | Bruker acquired Elitech Group, NanoString Technologies, Nanophoton, Chemspeed Technologies, PhenomeX, Biocrates Life Sciences, Inscopix, RECIPE, Biognosys, Nion, and 23 other companies. |
| In how many companies Bruker has invested to date? | As of September 2026, Bruker has invested in 10 companies. |
| What was the last Bruker investment? | On 11th August 2026 Bruker invested in Atinary, participating in a Strategic investment round. |
| In what companies Bruker invested in? | Bruker invested in Tome Biosciences, Mercy BioAnalytics, Haystack Oncology, PrognomiQ, Ionpath, KIYATEC, PreOmics, Terrain Bio, Navignostics, and Atinary. |
See public comps similar to Bruker
Lists including Bruker
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.









